Dr. Edwards has served as an Independent Non-Executive Director on the board of directors since April 2019.
Dr. Edwards has significant experience in investing and contributing to the development of biotech companies in both Europe and the US. Dr. Edwards currently serves on the boards of directors of Kalvista Pharmaceuticals, Inozyme Pharma, Morphic Therapeutic, and Reata Pharmaceuticals. Previously, he was Senior Partner at Novo Ventures from 2003-2020, and Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development. Dr. Edwards trained in physiology and medicine at the University of Manchester. He was elected a Member of the Royal College of Physicians, a Member with the distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine, and holds an MBA from the University of Warwick.